• pharma
  • pharmapharma

NEWSLETTER

Pharma Business Daily: Each issue of the Pharma Business Daily newsletter focuses on the latest market information. Delivered directly to your Inbox or available via our website, keep abreast of whatever you need to know, whenever you need to know it. 24/7, 365 days a year - it really is that simple. With over 25 breaking stories every day, never again will any of your colleagues be aware of news you aren't.

CONSULTANCY

With unparalleled knowledge of the markets we study, our consultants provide quality research specifically for you. We assist our clients in researching mergers and acquisitions, accessing new markets, competitor analysis, and negotiating and structuring deals. We can also advise clients strategically on advertising, marketing or PR.

Latest REPORTS

rss_Pharma.jpg...see all
  1. Pharmaceutical Contract Manufacturing: Industry and Market Prospects 2010-2025

    Pharmaceutical Contract Manufacturing: Industry and Market Prospects 2010-2025

    How will the contract manufacturing sector adapt to the needs of pharma from 2010 onwards? Our new report will show you trends and prospects there. How will the sector and its customers face challenges and opportunities? We show commercial benefits for the pharma contract manufacturing sector and its customers, including revenue trends for 2010-2025. You can have that report today, staying ahead.

    ...more details
  2. Biobanking for Medical R&D: Technology and Market 2010-2025

    Biobanking for Medical R&D: Technology and Market 2010-2025

    Biobanking for Medical R&D: Technology and Market 2010-2025 reveals the opportunities and challenges the biobanking sector will face. These include consolidation and harmonisation of biobanking practices. Advances in genetic research, stem cell research and regenerative medicine increase the importance of biobanking, as well as its commercial potential.

    ...more details
  3. Therapeutic Monoclonal Antibodies: World Market 2010-2025

    Therapeutic Monoclonal Antibodies: World Market 2010-2025

    In 2009, the therapeutic monoclonal antibodies market generated total revenues of over $35bn worldwide. From 2010 onwards, this sector will benefit from new drugs and expanding indications for existing products, our latest study shows. New technologies will be an important driver of revenue growth. Intensive R&D activity is producing a strong R&D pipeline, filled with novel monoclonal antibodies, antibody fragments and antibody-drug conjugates. We expect significant opportunities for further commercial growth, as discussed in our latest report.

    ...more details

Upcoming CONFERENCES

rss_Pharma.jpg...see all
  1. 4th Lyophilisation Conference

    4th Lyophilisation Conference

    7th - 9th September 2010, The Window, 13 Windsor Street, Islington, London, UK
    With over 130 products on the market worth $50bn, biologicals and biopharmaceuticals remain the fastest growing segment amongst novel pharmaceutical entities today. Mirroring this trend, the market for lyophilising these compounds, currently approaching 200 million units, is set to continue its year-on-year double digit growth.

    ...more details
  2. 4th Annual Pharmaceutical PLM

    4th Annual Pharmaceutical PLM

    14th - 15th September 2010, Thistle Marble Arch, London, UK
    Pharmaceutical and biopharmaceutical companies are under severe pressure to improve product pipelines, accelerate time to market, and improve margins on existing product, while maintaining strict adherence to quality principles and regulatory requirements. It is imperative that pharmaceutical and biotech companies address these business challenges to stay competitive, increase revenue, enhance profit, and reduce the risk of noncompliance.

    ...more details
  3. CNS Clinical Trials

    CNS Clinical Trials

    16th - 17th September 2010, Thistle Marble Arch, London, UK
    CNS is one of the largest and fastest growing therapeutic areas of the pharmaceutical market. The ageing of the baby-boom generation combined with new and emerging treatments for neurodegenerative disorders, including multiple sclerosis, Alzheimer's disease and Parkinson's disease, will lead to further expansion of the neurodegenerative therapies market.

    ...more details